Compare Digital Realty Trust, Inc. (DLR) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Medtronic PLC — how do they compare? Digital Realty Trust, Inc. trades at $177.52 (market cap $65.32B), while Medtronic PLC trades at $87.75 (market cap $112.24B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Medtronic PLC for 63 Days on average.
| DLR | MDT | |
|---|---|---|
Market Cap | $65.32B | $112.24B |
Volume | 2,563,950 | 105,663,236 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $105.35 |
52-Week Low | $147.93 | $73.75 |
Typical Hold Time | 94 Days | 63 Days |
Enterprise Value | $84.03B | $131.58B |
Dividend Yield | 2.77% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $180.47, down 2.26% today, with a bearish technical signal. The stock shows strong fundamentals: revenue grew to $6.11B in 2025, net income margin improved to 21.4%, and Q2 2026 EPS beat expectations. Analysts are overwhelmingly bullish with a $222.35 consensus target. Recent news highlights AI infrastructure expansion, including a partnership with Blackfuel and a new cable landing station in Los Angeles, driving positive sentiment.
Outlook is positive due to robust AI-driven demand and record leasing activity, but risks include high valuation (P/E 88.03) and significant capital expenditures. Net cash flow turned negative in 2025, and debt levels remain elevated. The stock offers growth potential from the AI boom, yet investors should weigh execution risks and macroeconomic sensitivity.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
